Publications by authors named "Tess Marchetti"
Objectives: aPL are frequently present in SLE. In a well characterized SLE cohort we aimed at investigating the prevalence of aPL and assessing their analytical performance and clinical association by testing criteria specificities including LA, aCL IgG and IgM, anti-β2-glycoprotein 1 (antiβ2GP1) IgG and IgM, as well as the non-criteria aPS-PT IgG and IgM and anti-β2GP1 domain 1 (aD1) IgG.
Methods: We included 178 patients satisfying the ACR SLE classification criteria, from whom 283 samples and thrombotic events were collected longitudinally.
Obstetrical antiphospholipid syndrome (APS) is defined by obstetrical complications and the presence of antiphospholipid antibodies (aPL). Although the incidence of APS is still poorly known, this thrombophilia is now recognized as one of the most common acquired causes of recurrent fetal loss. The diagnosis of APS during pregnancy can be challenging because of its various clinical features.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on pregnancy outcomes in women with the obstetric form of antiphospholipid syndrome (APS) treated with low-molecular-weight heparin (LMWH) and low-dose aspirin (LDA), highlighting a lack of current documentation on this topic.
- APS women with a history of fetal loss were found to have increased risks of complications like preeclampsia (PE), premature birth, and other placenta-related issues compared to women without APS.
- The research suggests that while the LMWH + LDA treatment may lower overall pregnancy loss in APS women, these patients still face higher rates of PE, indicating a need for improved therapies targeting late pregnancy complications based on the type of previous pregnancy loss.